To confirm significant improvement of the skin score in systemic sclerosis by treatment with interferon gamma in a larger group of patients and to investigate on a molecular level the influence of interferon gamma on collagen type I messenger RNA expression.
Open, noncontrolled multicenter study. Setting: Five outpatient clinics specializing in the care of systemic scleroderma.
Thirty-two patients suffering from the diffuse or limited form of systemic sclerosis and progressive disease were recruited; 20 patients finished the study.
Each patient received interferon gamma, 50 μg subcutaneously 3 times a week for 1 year.
Main Outcome Measure:
Skin score, collagen type I messenger RNA in skin biopsy specimens.
The patients who completed the study showed an unchanged median skin score after 1 year of therapy. In addition, similar collagen type I messenger RNA levels were detected in skin biopsy specimens taken from involved skin before and after therapy in these patients.
Treatment of systemic scleroderma with interferon gamma is associated with stabilization of the skin score and lack of worsening of visceral involvement.Arch Dermatol. 1997;133:609-613
Hunzelmann N, Anders S, Fierlbeck G, et al. Systemic Scleroderma: Multicenter Trial of 1 Year of Treatment With Recombinant Interferon Gamma. Arch Dermatol. 1997;133(5):609–613. doi:10.1001/archderm.1997.03890410065008
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.